nuebe gaming 888 login register online

A Chinatown resident took the City of Vancouver and the Vancouver Police Department to court over a surveillance truck parked near her apartment. Karina Papenbrock-Ryan alleged the VPD violated her privacy and charter rights when it left its surveillance trailer on East Pender Street four years ago. The force calls the machine its . It consists of cameras and other equipment mounted on wheels. Police placed it outside the Chinese Cultural Centre in April 2020 in response to racist graffiti referencing COVID-19, the holocaust, and threatening violence against Asian people. The trailer was about one and a half blocks from Papenbrock-Ryan’s condominium. She estimated she walked through its field of view about 10 times without knowing what it was. When she saw a social media post explaining that it had cameras, she decided to modify her route so she wouldn’t walk past it anymore. “Ms. Papenbrock-Ryan describes this action as a test case dealing with the rights of the public to be free from mass surveillance by means of video cameras deployed in a public place or, put differently, general video surveillance without a specific investigative purpose,” judge Bruce Elwood wrote in his . Elwood dismissed Papenbrock-Elwood’s action but thanked her for bringing it forward. The case focused on whether her privacy was breached. Elwood explained there are already laws governing continually recorded police surveillance of public spaces, facial recognition technology, collection of personal information by the VPD, targeted surveillance during a criminal investigation, and the admissibility of video evidence during a criminal trial. The surveillance trailer records its video locally on a hard drive that’s wiped clean every four days unless an officer tries to access it. Though the judge accepted that Papenbrock-Elwood would have walked through its field of view, there’s nothing to suggest that a VPD officer accessed, reviewed, or distributed any images of her. Given the totality of circumstances, the judge didn’t think her privacy was violated. “At most, the footage of Ms. Papenbrock-Ryan would have disclosed her gender, her general appearance, her direction of travel, her mode of travel, and the date and time when she passed by,” the judge wrote. “It would not have revealed where she lives, where she works, where she was going, her religious or political beliefs, with whom she associates or any other biographical information about her.” Pepenbrock-Elwood’s privacy concerns also had to be balanced against community concerns following the hateful graffiti. “Provided it was working at the time, the [trailer] may have recorded a criminal act in progress, an image of a suspect, their direction and mode of travel, etc.” the judge wrote. “However, its primary purposes were to serve as a physical and psychological deterrent, and to reassure the community.” The judge looked at screenshots from the trailer and estimated its field of view at about 40 square metres. Its cameras were aimed at the Chinese Cultural Centre. The surveillance trailer ended up being removed in June 2020. It suffered technical difficulties that led to it not recording for several days. During that time, the trailer itself was tagged with graffiti.nuebe gaming 888 login register online 。

FedEx Corp. stock underperforms Tuesday when compared to competitors

Graphene Market to Reach USD 4997.1 Million by 2032 Driven by Advancements in Healthcare and Electronics Applications, Says SNS InsiderStock image Stock image Westlink stock photo. Here’s the latest traffic and travel news from around Northern Ireland. Stock image Watch: Belfast Hotel unveils life-sized gingerbread house

Patient advocates call for more support for Australian workers living with a chronic condition/s following the release of a new insights report SYDNEY , Dec. 4, 2024 /PRNewswire/ -- A new report released today has found that of the one in two Australians living with a chronic health condition/s, over a third (37%) have left a job due to their condition/s. The two leading reasons individuals leave are: stress from work exacerbating their condition/s (56%); and lack of support in the workplace (44%). The new Insights Report: Working Well - Creating Workplace Cultures to Unlock the Full Capabilities of Australians Living with Chronic Health Conditions, commissioned by AbbVie, explores the experiences of Australians in the workforce living with chronic health conditions. In addition, the report analyses the broader attitudes of Australians in the workplace towards working and supporting those with chronic conditions, and where opportunities lie to improve or introduce workplace education and support measures. The report uncovered that stigma and discrimination towards those living with a chronic condition/s is still highly prevalent in Australian workplaces, with almost one in five (19%) of Australian workers with a chronic health condition admitting they left their job because they were discriminated against. Concerningly, 77% of Australian workers believe individuals living with a chronic condition/s experience discrimination and stigma at work, and fear of stigma and discrimination is the most common reason those living with a chronic condition/s do not disclose their condition/s to their employers (51%). Deidre Mackechnie , Executive Officer at the Australian Patient Advocacy Alliance (APAA), said: "The Working Well Insights Report launched today provides crucial insights into the unique experiences and challenges of Australian workers living with chronic health conditions: including why individuals may or may not choose to disclose their condition; where workers go to for advice and support; and the impact their condition/s have on career planning and progression." "The report also highlights the key areas that Australian workers believe their employers can do more to support people with chronic conditions, such as improving flexible working hours, support to take time for medical appointments or treatments and workplace policies to support individuals. "We understand that every individual has their own unique needs based on their condition, and there is no standard workplace policy or support measure that will cater to all these needs. However, our hope is that this report can be used to start a conversation in the workplace on how employers and co-workers can better support those with chronic conditions and that these conversations will help to reduce the stigma and discrimination these individuals face," said Ms Mackechnie. Positively, data in the report shows a clear consensus from the broader Australian workforce that it is important for people with a chronic health condition to have opportunities to stay in the workforce (85%). More than four in five (83%) want training to learn how to support better individuals living with a chronic condition at work. Nathalie McNeil , Vice President and General Manager of AbbVie Australia & New Zealand, said: "We know that the burden of chronic health conditions is continuing to rise, with data released earlier this month showing Australia spent $82 billion on chronic health conditions between 2022 and 2023. However, there has been little research into the role workplaces play to maximise workplace participation, especially for those living with chronic health conditions, to help reduce the financial, social and emotional burden." Australia's expenditure on managing chronic health conditions accounted for nearly half (48%) of total healthcare expenditure in 2022-23. Furthermore, from 2013-14 to 2022-23, total spending on disease and injury rose by $70.5 billion , 54% of which was driven by increase in spending for chronic conditions. "At AbbVie, we are committed to providing a welcoming environment for all our employees, including those living with chronic conditions. We are using the findings of the Working Well report to explore how we can better support those colleagues living with chronic health condition/s in order to create a more inclusive and supportive workplace for all employees. "In 2025 we aim to work with other employers and organisations to discuss how we can better support Australians living and working with a chronic condition/s," said Ms McNeil. The full Insights Report: Working Well - Creating Workplace Cultures to Unlock the Full Capabilities of Australians Living with Chronic Health Conditions is available here .

10x Genomics Logo (PRNewsfoto/10x Genomics, Inc.) PLEASANTON, Calif. , Dec. 23, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced today it had secured a permanent injunction in the U.S. District Court for the District of Delaware against the GeoMx products sold by Bruker Corporation (Nasdaq: BRKR), which acquired the product line from NanoString Technologies. To minimize the risk of disruption to ongoing research, 10x Genomics requested a carve-out for GeoMx users who installed an instrument prior to the trial in November 2023 . The injunction, which the Court said it will enter in January 2025 , is expected to prohibit Bruker from making, using, selling or offering to sell in the United States its GeoMx Digital Spatial Profiler and associated instruments, reagents and services for RNA and protein detection. At the request of 10x Genomics, the injunction will not block ongoing research by researchers who installed a GeoMx instrument prior to November 18, 2023 . Such customers can continue to purchase GeoMx reagents for use with existing GeoMx instruments for purposes of continuing their ongoing research. The Court found that making such an exception for ongoing research strikes a "workable balance between protecting the patentee's rights and protecting the public from the injunction's adverse effects." In addition, the Court affirmed the $31 million damages awarded by the November 2023 jury verdict, as well as supplemental damages and interest that will be added to the total damages when final judgment is entered. "Today's decision helps to safeguard our decade-long investment in innovation and ensures we can continue to develop groundbreaking technologies that help our customers revolutionize science," said Eric Whitaker , Chief Legal Officer at 10x Genomics. "10x exists to fuel scientific progress – not stifle it – and that is why we've done our utmost to ensure this injunction was structured to protect both our intellectual property and existing GeoMx customers' ongoing research." The Court recognized the harm NanoString's infringing conduct caused 10x when it wrote in its ruling, "Having been careful not to license its technology, 10x suffers when it proclaims itself as an innovator in spatial genomics but a competitor is using the same innovative, patented technology." Today's Court decision follows a November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys. During the trial, the jury heard testimony from the sole inventor of the patents, Illumina co-founder Mark Chee , and NanoString CEO Brad Gray and NanoString CSO Joe Beechem. After hearing all of the evidence, the jury determined that all seven patents had been infringed by NanoString, that each patent was valid, that NanoString willfully infringed those patents and that monetary damages were owed to 10x for the infringement of all seven patents. In affirming the jury's finding that NanoString willfully infringed, the Court relied on the evidence showing that NanoString knew or was willfully blind that its acts would cause infringement of 10x's rights. The asserted patents in Case No. 21-cv-653-MFK include (a) U.S. Patent No. 10,472,669; (b) U.S. Patent No. 10,961,566; (c) U.S. Patent No. 10,983,113; (d) U.S. Patent No. 10,996,219; (e) U.S. Patent No. 11,001,878; (f) U.S. Patent No. 11,008,607 and (g) U.S. Patent No. 11,293,917. About 10x Genomics 10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomics.com or connect with us on LinkedIn or X (Twitter) . Forward Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 as contained in Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. All statements included in this press release, other than statements of historical facts, may be forward-looking statements. Forward-looking statements generally can be identified by the use of forward-looking terminology such as "may," "might," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "see," "estimate," "predict," "potential," "would," "likely," "seek" or "continue" or the negatives of these terms or variations of them or similar terminology, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include statements regarding litigation and remedies as well as possible outcomes of litigation. These forward-looking statements do not reflect that our success will depend on our ability to obtain, maintain and protect our intellectual property rights, intellectual property litigation could be expensive, time-consuming, unsuccessful and could interfere with our ability to develop, manufacture and commercialize our products or technologies, litigation outcomes are unpredictable or there may be changes in our litigation strategy. These statements are based on management's current expectations, forecasts, beliefs, assumptions and information currently available to management. Actual outcomes and results could differ materially from these statements due to a number of factors and such statements should not be relied upon as representing 10x Genomics, Inc.'s views as of any date subsequent to the date of this press release. 10x Genomics, Inc. disclaims any obligation to update any forward-looking statements provided to reflect any change in 10x Genomics' expectations or any change in events, conditions or circumstances on which any such statement is based, except as required by law. The material risks and uncertainties that could affect 10x Genomics, Inc.'s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the company's most recently-filed 10-K for the fiscal year ended December 31, 2023 and elsewhere in the documents 10x Genomics, Inc. files with the Securities and Exchange Commission from time to time. Disclosure Information 10x Genomics uses filings with the Securities and Exchange Commission, our website ( www.10xgenomics.com ), press releases, public conference calls, public webcasts and our social media accounts as means of disclosing material non-public information and for complying with our disclosure obligations under Regulation FD. Contacts Investors: investors@10xgenomics.com Media: media@10xgenomics.com View original content to download multimedia: https://www.prnewswire.com/news-releases/us-district-court-awards-10x-genomics-permanent-injunction-in-patent-infringement-lawsuit-against-bruker-corporations-geomx-products-302338627.html SOURCE 10x Genomics, Inc.Global stocks end mostly up with DAX crossing 20,000 for 1st timeProsecutors: Brooklyn businessman will plead guilty to conspiracy charge in case against Mayor Adams

Packham resigns as RSPCA president after animal cruelty claims at approved farms

Plan to add resources to border will come before Trump inauguration: LeBlancA look at how some of Trump's picks to lead health agencies could help carry out Kennedy's overhaul

Congress faces government funding deadline after ThanksgivingStock market today: Wall Street rises at the start of a holiday-shortened week

MURFREESBORO, Tenn. (AP) — Brandon Nunez threw just two passes, each for a score, and New Mexico State beat Middle Tennessee 36-21 on Saturday to end a three-game losing streak. Nunez tossed a 12-yard touchdown pass to Seth McGowan to give the Aggies a 20-7 lead midway through the third quarter. After Middle Tennessee pulled to 26-21 early in the fourth, Nunez tossed a 4-yard TD pass to Cooper Sheehan that made it 33-21 with 7:43 left. Parker Awad completed 12 of 16 passes for 221 yards for New Mexico State (3-8, 2-5 Conference USA). McGowan finished with 83 yards rushing. Mike Washington also had a touchdown run and Dylan Early a 30-yard pick-6 for the Aggies. Nicholas Vattiato was 30-of-45 passing for 277 yards with two touchdowns and two interceptions for Middle Tennessee (3-8, 2-5), which has lost three of its last four. __ Get alerts on the latest AP Top 25 poll throughout the season. Sign up here ___ AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

Is Flyers' Matvei Michkov trending to be better than Blackhawks' Connor Bedard?

Vikings waive former starting cornerback Akayleb Evans in another blow to 2022 draft class

Man City routed 4-0 by Tottenham in fifth-straight defeat as crisis deepens for Pep Guardiola